GRAIL, Inc.

NASDAQ:GRAL

Medical - Diagnostics & Research

Healthcare
$102.10 +3.20%

+$1.90 today

Market cap
$4.59B
Beta
3.16
P/E (TTM)
-6.3
EPS (TTM)
-$9.73
52W Low $29.95High $118.84

Volume 0.62M

Average 0.77M

GRAL Net Debt

Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.

GRAIL, Inc.NASDAQ: GRAL

Net Debt · Q2 FY2026 · quarter ended Jun 2026

Net debt turns positive

Q2 FY2026 net debt was $35.66M, compared with -$65.26M a year earlier.

Context

  • Net debt amounted to 1.3% of total assets at the end of Q2 FY2026, down 1.2 pp from a year earlier.
  • Net debt grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net debt keeps rising in the next quarterly balance sheet after a +154.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$35.66M+294.7% QoQ
Last fiscal yearDec 2025
-$151.72M-3.8% YoY
Year agoJun 2025
-$65.26M+154.6% since
Net Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+154.6%——
1 year-3.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Debt history

USD · from the balance sheet

Latest · FY2025
(151.72M) USD
Year-over-year change
-3.8%

Net Debt vs competitors

How GRAL compares with its peers on the latest reported figures

  • GRAL's Jun 2026 net debt of $35.66M is the 5th highest of the 10 companies compared; the peer median is -$13.23M.
  • Its year-over-year change of +154.6% is the 2nd highest of 10, against a peer median of +17.8%.
  • Net debt amounts to 1.3% of total assets for GRAL, versus a peer median of 22.2%.
GRAL Competitors Peer median
Net Debt for GRAL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GHGuardant Health, Inc.Sep 2026$664.59M -11.0%+2.8%35.2%
NEONeoGenomics, Inc.Jun 2026$302.83M +17.8%-3.5%22.4%
WGSGeneDx Holdings Corp.Jun 2026$107.09M +166.0%—22.2%
MYGNMyriad Genetics, Inc.Mar 2026$87.1M +32.4%-11.9%12.9%
GRALGRAIL, Inc.Jun 2026$35.66M +154.6%—1.3%
FLGTFulgent Genetics, Inc.Mar 2026-$13.23M +77.8%—1.1%
CSTLCastle Biosciences, Inc.Mar 2026-$27.04M +57.6%—4.9%
PSNLPersonalis, Inc.Mar 2026-$34.81M -31.0%—10.7%
BLLNBillionToOne, Inc.Jun 2026-$404.71M -392.1%—55.5%
NTRANatera, Inc.Jun 2026-$853.01M -6.1%—32.1%
Peer median (excluding GRAL) -$13.23M+17.8%-3.5%22.2%

Competitors are the stored peer set for GRAL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents221.16M241.6M97.29M214.23M249.73M
Short-term Investments000549.24M654.7M
Net Receivables6.88M18.62M22.35M24.64M18.3M
Inventory019.76M21.7M18.63M16.02M
Other Current Assets6.89M00015.11M
Total Current Assets242.73M295.63M156.07M819.86M953.85M
Property, Plant & Equipment (Net)216.37M198.72M169.38M135.43M103.88M
Goodwill6.2B1.5B888.94M00
Intangible Assets3.07B2.94B2.69B2.02B1.85B
Long-term Investments04.53M4.23M06.97M
Tax Assets0664.12M643.11M00
Other Non-current Assets7.1M6.14M7.98M11.12M6.75M
Total Non-current Assets9.5B5.31B4.4B2.16B1.97B
Total Assets9.74B5.6B4.56B2.98B2.92B
Account Payables17.65M17.48M19.67M4.84M2.08M
Short-term Debt013.34M14.81M011.72M
Tax Payables00000
Deferred Revenue0001.6M0
Other Current Liabilities4.51M65.96M87.64M22.69M65.87M
Total Current Liabilities97.89M134.94M163.61M76.93M79.67M
Long-term Debt000043.15M
Deferred Tax Liabilities0735.19M676.03M345.86M218.58M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities112.76M3.13M1.5M2.24M(40.4M)
Total Non-current Liabilities209.51M821M747.13M402.98M264.48M
Total Liabilities307.4M955.94M910.74M479.9M344.15M
Common Stock10.34B10.96B11.42B34K40K
Retained Earnings(911.54M)(6.31B)(7.78B)(9.8B)(10.21B)
Accumulated OCI315K894K1.07M1.45M2.66M
Other Stockholders Equity10100
Minority Interest00000
Total Equity9.43B4.65B3.65B2.5B2.58B
Total Debt110.56M96.01M84.41M68.14M98.01M
Net Debt(110.6M)(145.59M)(12.88M)(146.09M)(151.72M)

GRAIL, Inc.

NASDAQ:GRAL

Intrinsic Alpha fair value

Locked

Current Price

$102.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.